Naveen Pemmaraju, Director of Leukemia-Cancer Network, Executive Director of Cancer Medicine, Director of BPDCN at the Department of Leukemia, and Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a post on X about a paper he co-authored with colleagues published in Blood Neoplasia:
“Our group’s new paper, led by Dr C DiNardo and Dr K Bhalla. Omacetaxine + VEN in patients with R/R MDS/AML with RUNX1 mutation.”
Title: Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Authors: Courtney D. DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, Xuemei Wang, Sanam Loghavi, Sravanthi Lavu, Nicholas J. Short, Kelly Chien, Ghayas C. Issa, Naveen Pemmaraju, Musa Yilmaz, Michael Andreeff, Gautam Borthakur, Tapan M. Kadia, Naval G. Daver, Guillermo Garcia-Manero, Christopher P. Mill, Xiaoping Su, Warren Fiskus, and Kapil N. Bhalla
You can read the Full Article in Blood Neoplasia.
More posts featuring Naveen Pemmaraju.
